% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Beyer:180719,
      author       = {L. Beyer and H. Stocker$^*$ and D. Rujescu and B. Holleczek
                      and J. Stockmann and A. Nabers and H. Brenner$^*$ and K.
                      Gerwert},
      title        = {{A}myloid-beta misfolding and {GFAP} predict risk of
                      clinical {A}lzheimer's disease diagnosis within 17 years.},
      journal      = {Alzheimer's and dementia},
      volume       = {19},
      number       = {3},
      issn         = {1552-5260},
      address      = {Hoboken, NJ},
      publisher    = {Wiley},
      reportid     = {DKFZ-2022-01510},
      pages        = {1020-1028},
      year         = {2023},
      note         = {#EA:C070# / Volume19, Issue3, March 2023, Pages 1020-1028},
      abstract     = {Blood-based biomarkers for Alzheimer's disease (AD) are
                      urgently needed. Here, four plasma biomarkers were measured
                      at baseline in a community-based cohort followed over 17
                      years, and the association with clinical AD risk was
                      determined.Amyloid beta (Aβ) misfolding status as a
                      structure-based biomarker as well as phosphorylated tau 181
                      (P-tau181), glial fibrillary acidic protein (GFAP), and
                      neurofilament light (NfL) concentration levels were
                      determined at baseline in heparin plasma from 68
                      participants who were diagnosed with AD and 240 controls
                      without dementia diagnosis throughout follow-up.Aβ
                      misfolding exhibited high disease prediction accuracy of AD
                      diagnosis within 17 years. Among the concentration markers,
                      GFAP showed the best performance, followed by NfL and
                      P-tau181. The combination of Aβ misfolding and GFAP
                      increased the accuracy.Aβ misfolding and GFAP showed a
                      strong ability to predict clinical AD risk and may be
                      important early AD risk markers. Aβ misfolding illustrated
                      its potential as a prescreening tool for AD risk
                      stratification in older adults.},
      keywords     = {Alzheimer's disease (Other) / blood biomarkers (Other) /
                      immuno-infrared sensor (Other) / risk stratification (Other)
                      / single molecule array (Other)},
      cin          = {C070},
      ddc          = {610},
      cid          = {I:(DE-He78)C070-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:35852967},
      doi          = {10.1002/alz.12745},
      url          = {https://inrepo02.dkfz.de/record/180719},
}